Founder, President, and Scientific Director, D.Sc.
Douglas Lewis oversees the development of new matrices for use in diagnosing substances of abuse.
Lewis’s research record includes co-principal investigator on a $6.57 million NIDA funded grant entitled “Prenatal Methamphetamine Exposure and Child Outcome,” co-investigator on three Small Business Innovation Research (SBIR) Phase I grants—“Diagnostic Viability of Umbilical Cord Specimens,” “Using Human Hair to Determine Long Term Alcohol Abuse” and “Hair Ethyl Glucuronide as a Long-Term Alcohol Biomarker”—and co-investigator on an SBIR Phase II grant “Diagnostic Viability of Umbilical Cord Specimens“.
Prior to USDTL, he spent five years in academia as an assistant professor of clinical pathology at Northwestern University Medical School while also serving as the head of the toxicology section at the Children’s Memorial Hospital in Chicago. During his tenure at Northwestern and Children’s, Lewis established the first non-Olympic anabolic steroids testing laboratory in the United States and was a toxicologist for the U.S. Weight Lifting Federation.